The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the health-related quality of life (HRQoL) outcomes from the CheckMate 8HW study (NCT04008030) of first-line nivolumab with ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC). Health-related quality of life (HRQoL) showed significant improvements in the checkpoint inhibitor arm. Patients on nivolumab and ipilimumab reported better Global Health Status and fewer symptoms, with a reduced risk of HRQoL deterioration. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
